Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonardo Malimpensa

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Multiple Sclerosis and Related Disorders|May 29, 2024
The multidimensional assessment of body representation and interoception in multiple sclerosisSimona Raimo, Gina Ferrazzano, Antonella Di Vita, et al.
International Journal of Molecular Sciences|June 27, 2024
Exploring miRNAs' Based Modeling Approach for Predicting PIRA in Multiple Sclerosis: A Comprehensive AnalysisTommaso Gosetti di Sturmeck, Leonardo Malimpensa, Gina Ferrazzano, et al.
Biology|April 28, 2023
Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious RiskMaria Antonella Zingaropoli, Patrizia Pasculli, Matteo Tartaglia, et al.
Frontiers in Immunology|December 19, 2022
Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccineFederica Dominelli, Maria Antonella Zingaropoli, Matteo Tartaglia, et al.
Frontiers in Immunology|December 28, 2023
Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patientsIvan Arisi, Leonardo Malimpensa, Valeria Manzini, et al.
Multiple Sclerosis and Related Disorders|March 11, 2023
Frailty and relapse activity in multiple sclerosis: A longitudinal observationViola Baione, Marco Canevelli, Daniele Belvisi, et al.
European Journal of Neurology|March 29, 2024
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)Irene Schiavetti, Alessio Signori, Angela Albanese, et al.
Neurology and Therapy|September 19, 2025
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of FrailtyGina Ferrazzano, Roberta Fantozzi, Shalom Haggiag, et al.
Therapeutic Advances in Neurological Disorders|December 31, 2025
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian studyMatteo Lucchini, Giovanna Borriello, Shalom Haggiag, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Multiple Sclerosis and Related Disorders|May 29, 2024
The multidimensional assessment of body representation and interoception in multiple sclerosisSimona Raimo, Gina Ferrazzano, Antonella Di Vita, et al.
International Journal of Molecular Sciences|June 27, 2024
Exploring miRNAs' Based Modeling Approach for Predicting PIRA in Multiple Sclerosis: A Comprehensive AnalysisTommaso Gosetti di Sturmeck, Leonardo Malimpensa, Gina Ferrazzano, et al.
Biology|April 28, 2023
Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious RiskMaria Antonella Zingaropoli, Patrizia Pasculli, Matteo Tartaglia, et al.
Frontiers in Immunology|December 19, 2022
Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccineFederica Dominelli, Maria Antonella Zingaropoli, Matteo Tartaglia, et al.
Frontiers in Immunology|December 28, 2023
Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patientsIvan Arisi, Leonardo Malimpensa, Valeria Manzini, et al.
Multiple Sclerosis and Related Disorders|March 11, 2023
Frailty and relapse activity in multiple sclerosis: A longitudinal observationViola Baione, Marco Canevelli, Daniele Belvisi, et al.
European Journal of Neurology|March 29, 2024
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)Irene Schiavetti, Alessio Signori, Angela Albanese, et al.
Neurology and Therapy|September 19, 2025
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of FrailtyGina Ferrazzano, Roberta Fantozzi, Shalom Haggiag, et al.
Therapeutic Advances in Neurological Disorders|December 31, 2025
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian studyMatteo Lucchini, Giovanna Borriello, Shalom Haggiag, et al.
Pageof 2